Biostock writes about Elicera and CAR T-cells
CAR T-cell therapies have shown transformational potential for the treatment liquid tumours. The recent approval of Bristol Myers Squibb’ multiple myeloma CAR T drug Abecma brings the number of CAR T therapy approvals up to five, with three coming during the last year alone. However, despite the remarkable innovation and excitement surrounding this technology, major challenges still remain, especially with regard to solid tumour treatments. Swedish gene therapy company Elicera may have what it takes to get past these hurdles.
Elicera recruits CFO
Elicera recruits Ingvar Karlsson as CFO.
Ingvar has extensive experience from CFO positions in both public and private companies, including listed cell therapy company Idogen.
Daily Mail writes about Elicera
For more information, please read the article in the link below.
Elicera Therapeutics completes oversubscribed share issue and secures 13,2 MSEK in financing
Elicera Therapeutics announced today that it has completed its first share issue and secured 13,2 MSEK in financing to launch unique immuno-oncology company based on groundbreaking research by professor Magnus Essand's research group at Uppsala University. Jamal El-Mosleh is announced as Elicera's CEO.
Immuno-Oncology News writes about Elicera's CAR T-cell program
"Researchers at Uppsala University, in Sweden, in collaboration with the SciLifeLab Drug Discovery and Development Platform, have taken “a large step forward” in developing a potential CAR T-cell therapy for glioblastoma, an aggressive form of brain cancer that is often difficult to treat.
Their project is now entering the final preclinical stage of development, according to the university. The goal is to start clinical studies within four years."
Financial Times writes about Elicera
Financial Times writes an article about Elicera Therapeutics and the donation of shares to the VictoryNET-foundation.
Successfull collaborative project with Drug Development and Discovery Platform (DDD) at SciLifeLab completed
The successful collaborative project between Magnus Essand and Di Yu on one hand and the Drug Development and Discovery Platform (DDD) at SciLifeLab on the other reached the Exit Milestone after two and a half years. The project led to the development of a chimeric antigen receptor (CAR) targeting IL13R2a (ELC-401).
https://uu.se/en/news-media/news/article/?id=14932&typ=artikel&lang=en
The DDD Platform is a National Resource that helps researcher take academic findings into commercial product development.
Di Yu is awarded the Göran Gustafsson Stiftelse Prize in Medicine for Young Researchers
Di Yu is awarded the prestigious Göran Gustavsson Prize by the Royal Swedish Academy of Sciences for his research in CAR T-cells and oncolytic viruses.
Funding from the Sjöberg Foundation
Professor Magnus Essand is awarded SEK 6 million in funding from the Sjöberg Foundation for the development of ELC-401.
Funding by the Swedish Cancer Society
Professor Magnus Essand is granted SEK 13.5 million in funding by the Swedish Cancer Society for the development of ELC-301 and ELC-401.
Status update by Uppsala University on the clinical phase I/II-study in NET
Uppsala University provides a status update in short video clip of the ongoing phase I/II-study in NET.
The Medical Journal writes about a clinical study
The Medical Journal (Läkartidningen) writes about a clinical study with an oncolytic virus that was financed with a total of SEK 14 million via crowdfunding (ELC-100)
Swedish Public Radio interviews Professor Magnus Essand
Swedish Public Radio interviews Professor Magnus Essand on the occasion of securing crowdfunding to initiate a clinical study with the oncolytic virus AdVince (ELC-100).
Immunicum AB acquires patent from VirEx AB (Elicera Therapeutics)
Immunicum AB acquires a patent from VirEx AB (now Elicera Therapeutics) and simultaneously gives an exclusive global license for the development of an oncolytic virus (ELC-100) for the treatment of neuroendocrine tumors.
Successful crowdfunding
Planning of a clinical study with oncolytic virus (ELC-100), commences after successful crowdfunding. Background: Author and freelance journalist Alexander Masters from England contacts Professor Magnus Essand to explore the possibilities of using the oncolytic virus to treat a friend and colleague affected by NET. Professor Essand informs that funding to start a clinical trial is lacking which Alexander Masters subsequently writes about in the British newspaper "The Telegraph" where he also suggests that anyone who donates a million British pounds should have the virus named after him. The article gets wide spread attention and a crowdfunding campaign, iCancer, is initiated by Alexander Masters, Dominic Nutt and Liz Scarff to get the funds needed for a clinical trial in NET. As a result, thousands of people from around the world together donate a substantial sum for the cause of which the majority by oil tycoon Vince Hamilton, himself affected by NET. The oncolytic virus is named AdVince after him.
